Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

330 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Australasian Consensus Statement on the Identification, Prevention, and Management of Hormonal Crises in Patients with Neuroendocrine Neoplasms Undergoing Peptide Receptor Radionuclide Therapy.
Li M, Chan DL, Tapia Rico G, Cehic G, Lawrence B, Wyld D, Pattison DA, Kong G, Hicks R, Michael M, Kiberu AD, Lim J, Clifton-Bligh R, Tsang V, Roach PJ, Leyden J, Diakos CI, Price TJ, Pavlakis N. Li M, et al. Among authors: roach pj. Neuroendocrinology. 2023;113(3):281-288. doi: 10.1159/000526848. Epub 2022 Sep 1. Neuroendocrinology. 2023. PMID: 36049462 Free article. Review.
Prognostic and predictive biomarkers in neuroendocrine tumours.
Chan DL, Clarke SJ, Diakos CI, Roach PJ, Bailey DL, Singh S, Pavlakis N. Chan DL, et al. Among authors: roach pj. Crit Rev Oncol Hematol. 2017 May;113:268-282. doi: 10.1016/j.critrevonc.2017.03.017. Epub 2017 Mar 18. Crit Rev Oncol Hematol. 2017. PMID: 28427516 Review.
Dual Somatostatin Receptor/FDG PET/CT Imaging in Metastatic Neuroendocrine Tumours: Proposal for a Novel Grading Scheme with Prognostic Significance.
Chan DL, Pavlakis N, Schembri GP, Bernard EJ, Hsiao E, Hayes A, Barnes T, Diakos C, Khasraw M, Samra J, Eslick E, Roach PJ, Engel A, Clarke SJ, Bailey DL. Chan DL, et al. Among authors: roach pj. Theranostics. 2017 Mar 1;7(5):1149-1158. doi: 10.7150/thno.18068. eCollection 2017. Theranostics. 2017. PMID: 28435454 Free PMC article.
Single-centre experience with peptide receptor radionuclide therapy for neuroendocrine tumours (NETs): results using a theranostic molecular imaging-guided approach.
Gordon S, Chan DLH, Bernard EJ, Eslick ME, Willowson KP, Roach PJ, Engel AF, Maher R, Clarke SJ, Agarwal V, Yasmin L, De Silva M, Mascall S, Conner A, Nevell D, Pavlakis N, Bailey DL. Gordon S, et al. Among authors: roach pj. J Cancer Res Clin Oncol. 2023 Aug;149(10):7717-7728. doi: 10.1007/s00432-023-04706-1. Epub 2023 Apr 1. J Cancer Res Clin Oncol. 2023. PMID: 37004598 Free PMC article.
Overall survival with [177Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): secondary outcomes of a randomised, open-label, phase 2 trial.
Hofman MS, Emmett L, Sandhu S, Iravani A, Buteau JP, Joshua AM, Goh JC, Pattison DA, Tan TH, Kirkwood ID, Ng S, Francis RJ, Gedye C, Rutherford NK, Weickhardt A, Scott AM, Lee ST, Kwan EM, Azad AA, Ramdave S, Redfern AD, Macdonald W, Guminski A, Hsiao E, Chua W, Lin P, Zhang AY, Stockler MR, Williams SG, Martin AJ, Davis ID; TheraP Trial Investigators and the Australian and New Zealand Urogenital and Prostate Cancer Trials Group. Hofman MS, et al. Lancet Oncol. 2024 Jan;25(1):99-107. doi: 10.1016/S1470-2045(23)00529-6. Epub 2023 Nov 30. Lancet Oncol. 2024. PMID: 38043558 Clinical Trial.
330 results